amlodipine besylate; indapamide; telmisartan - Profile

What are the generic sources for amlodipine besylate; indapamide; telmisartan and what is the scope of freedom to operate?

Amlodipine besylate; indapamide; telmisartan is the generic ingredient in one branded drug marketed by Azurity and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amlodipine besylate; indapamide; telmisartan has sixty-nine patent family members in twenty-two countries.

Summary for amlodipine besylate; indapamide; telmisartan

International Patents:	69
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for amlodipine besylate; indapamide; telmisartan

Constraining patent/regulatory exclusivity:

10,322,117

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for amlodipine besylate; indapamide; telmisartan

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	WIDAPLIK	amlodipine besylate; indapamide; telmisartan	TABLET;ORAL	219423-001	Jun 5, 2025		RX	Yes	No	10,322,117		Y
Azurity	WIDAPLIK	amlodipine besylate; indapamide; telmisartan	TABLET;ORAL	219423-001	Jun 5, 2025		RX	Yes	No	12,465,599		Y
Azurity	WIDAPLIK	amlodipine besylate; indapamide; telmisartan	TABLET;ORAL	219423-001	Jun 5, 2025		RX	Yes	No
Azurity	WIDAPLIK	amlodipine besylate; indapamide; telmisartan	TABLET;ORAL	219423-002	Jun 5, 2025		RX	Yes	No	10,799,487		Y
Azurity	WIDAPLIK	amlodipine besylate; indapamide; telmisartan	TABLET;ORAL	219423-002	Jun 5, 2025		RX	Yes	No	12,465,599		Y
Azurity	WIDAPLIK	amlodipine besylate; indapamide; telmisartan	TABLET;ORAL	219423-002	Jun 5, 2025		RX	Yes	No

International Patents for amlodipine besylate; indapamide; telmisartan

Country	Patent Number	Title	Estimated Expiration
Australia	2018213147	Compositions for the treatment of hypertension
Australia	2019309329	Compositions for the treatment of hypertension
Australia	2023274064	Compositions for the treatment of hypertension
Australia	2025201831	Compositions for the treatment of hypertension
Australia	2025287416	Compositions for the treatment of hypertension
Brazil	112019015368	composições para o tratamento de hipertensão

Supplementary Protection Certificates for amlodipine besylate; indapamide; telmisartan

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0502314	SPC/GB11/010	United Kingdom		PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK
1915993	C300625	Netherlands		PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
0443983	C300445	Netherlands		PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
0443983	2007C/043	Belgium		PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
1507558	12C0033	France		PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: CH - 6167801 20110705
0503785	C300486	Netherlands		PRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216

Investment Scenario and Fundamentals Analysis for Amlodipine Besylate, Indapamide, and Telmisartan

Last updated: February 10, 2026

Market Overview

The combination of antihypertensive medications like amlodipine besylate, indapamide, and telmisartan demonstrates strong growth potential driven by global cardiovascular disease prevalence, aging populations, and healthcare reforms favoring chronic disease management. The global antihypertensive drug market was valued at approximately $30 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 4% through 2027.

Compound-Specific Market Dynamics

Amlodipine Besylate

• Market Position: One of the most prescribed calcium channel blockers for hypertension and angina.
• Sales Data: Estimated global sales of $7.2 billion in 2022, with the United States dominating sales.
• Patent Status: Generic versions entered the market post-2014, leading to reduced exclusivity. Six major manufacturers produce generic amlodipine.
• Pricing: Due to generic competition, prices have declined substantially, impacting profit margins for brand-name and generic manufacturers.

Indapamide

• Market Position: Thiazide-like diuretic, used alone or in combination with other antihypertensives.
• Sales Data: Estimated to account for $1.2 billion globally in 2022.
• Patent Status: No patent protection since the 1980s; available as generic.
• Pricing: Low-cost drug, with margins heavily dependent on volume and manufacturing efficiency.

Telmisartan

• Market Position: Angiotensin II receptor blocker (ARB) with particular affinity for metabolic syndrome.
• Sales Data: Estimated global sales of $3.8 billion in 2022.
• Patent Status: Patent protection expired in most major markets by 2018; generic versions available.
• Pricing: Prices have declined in competitive markets, though brand-name formulations still command premiums in some regions.

R&D and Regulatory Landscape

• Development: The three drugs are established compounds with decades of clinical data, reducing the need for expensive R&D.
• Patent Expirations: Generics dominate the market. Innovator patents have largely expired, increasing price competition.
• Regulatory Approval: Regulatory pathways are well-defined. New formulations or fixed-dose combinations require substantial clinical trials, which may limit innovation but offer incremental growth.

Competitive Landscape

• Generic Market: Dominant players include Teva, Mylan (now part of Viatris), Sandoz, and several regional manufacturers.
• Brand-Name Holders: Pfizer, AstraZeneca, and others historically held patent rights for original formulations.
• Market Entry Barriers: Low due to the availability of established generics; innovation efforts focus on combination therapies or novel delivery systems.

Investment Considerations

Aspect	Details	Implications
Market Saturation	High levels of generics, especially for amlodipine and telmisartan	Margins pressure; focus on volume, cost control
Patent Landscape	Expired patents; limited exclusivity for new entrants	Increased competition; price erosion
Pricing Trends	Declining prices for generics	Revenue compression in mature segments
R&D Barriers	Low, given established compounds	Limited opportunity for breakthrough innovation
Regulatory Environment	Known and straightforward for generics	Faster product approval, lower costs

Financial Outlook

• Profits depend on manufacturing efficiency and market share retention.
• Growth prospects hinge on expanding fixed-dose combinations and entering emerging markets.
• Margin compression expected in mature markets due to intense competition.

Key Risks

• Pricing pressure from generics.
• Regulatory delays for new formulations.
• Market shifts towards combination therapies, requiring continuous innovation.
• Supply chain disruptions could affect manufacturing costs.

Conclusion

For investors, companies with established manufacturing capabilities, cost leadership, and strategic positioning in emerging markets are better positioned in this segment. Entrants willing to innovate through combination drugs or novel formulations may find niche opportunities, but sizable margins are unlikely without patent protections.

Key Takeaways

• The market for these drugs is mature, with significant generic competition.
• Revenue growth is limited but stable, driven by volume.
• Price erosion remains a concern, especially for low-cost generics.
• Innovation is limited to incremental improvements rather than novel entities.
• Success depends on cost management and geographic expansion.

FAQs

What is the outlook for generic drug prices in the antihypertensive market?

Prices trend downward due to increasing generic competition, especially post-patent expiration. Price erosion varies by region but generally remains significant in mature markets.

Are fixed-dose combinations (FDCs) a growth driver in this segment?

Yes. FDCs simplify treatment regimens, improve adherence, and are gaining acceptance in both developed and emerging markets. Companies investing in FDCs may gain competitive advantages.

How do regulatory hurdles impact new product development?

For established compounds like these, regulatory hurdles are lower for generics but significant for new formulations or combination therapies. Approval pathways are streamlined for generics but lengthy for novel drugs.

Which geographic markets offer the most growth potential?

Emerging markets, including Asia and Latin America, present growth opportunities due to increasing hypertension prevalence and lower regulatory barriers.

What is the risk of patent litigations or legal challenges?

While patent protections have expired or are close to expiry, patent litigations can delay generic entry or introduce marketing restrictions. Monitoring patent landscapes remains essential.

---

References

[1] Market Data: Global Antihypertensive Market Report 2022.
[2] Patent and Regulatory Updates: U.S. FDA and EMA databases.
[3] Industry Reports: IQVIA, Evaluate Pharma 2022.